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Abstract: Heterometallic titanocene-based compounds containing 
gold(I)-phosphane fragments have been extremely successful 
against renal cancer in vitro and in vivo. The exchange of 
phosphane by N-heterocyclic carbene ligands to improve or 
modulate their pharmacological profile afforded bimetallic complexes 
effective in prostate cancer but less effective in renal cancer in vitro. 
We report here on the synthesis of new bimetallic Ti-Au compounds 
by incorporation of two highly active gold(I)-N-heterocyclic carbene 
fragments previously reported derived from 4,5-diarylimidazoles. The 
two new compounds [(η5-C5H5)2TiMe(μ-mba)Au(NHC)] (NHC = 1,3-
Dibenzyl-4,5-diphenylimidazol-2-ylidene NHC-Bn 2a; 1,3-Diethyl-4,5-
diphenylimidazol-2-ylidene NHC-Et 2b) with the dual linker (-OC(O)-
p-C6H4-S-) containing both a carboxylate and a thiolate group were 
evaluated in vitro against renal, and prostate cancer cell lines. The 
compounds were more cytotoxic than previously described Ti-Au 
compounds containing non-optimized gold(I)-N-heterocyclic 
fragments. We present studies to evaluate their effects on cell death 
pathways, migration, inhibition of thioredoxin reductase (TrRx) and 
vascular endothelial growth factor (VEGF) in prostate PC3 cancer 
cell lines. The results support that the incorporation of a second 
metallic fragment like titanocene to biologically active gold(I) 
compounds improves their pharmacological profile. 
Introduction 
Metal-based drugs have experienced a resurgence as 
prospective cancer chemotherapeutics with a growing number of 
compounds active against tumors in vivo and some in current 
clinical trials.[1,2] Current efforts have been focused in the use on 
non-conventional metallodrugs (those with a mode of action 
different from that of cisplatin)[3,4] as well as in understanding 
their mode of action,[5] their effects in the immune system[6] and 
in developing agents that can be photoactivated[7] or delivery 
systems[8] that may improve their pharmacological profiles. The 
potential of heterometallic compounds (compounds with two or 
more different metals)  in cancer therapy has been recently 
highlighted.[9] The hypothesis (first described by Casini and co-
workers)[10] is that the incorporation of two different biologically 
active metals in the same molecule may improve their antitumor 
activity as a result of metal specific interactions with distinct 
biological targets (cooperative effect) or by the improved 
chemicophysical properties of the resulting heterometallic 
compound (synergism).  
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Figure 1. Second and third generation bimetallic compounds based on 
titanocene and gold(I) fragments with relevant anticancer properties.[5-7] 
Structure of cisplatin, Auranofin (AF), titanocene dichloride (TDC) and 
Titanocene-Y (Ti-Y) used as controls in some of the biological experiments or 
mentioned in the manuscript. 
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Our group at Brooklyn College has described a variety of 
compounds based on gold(I) biologically active fragments (either 
containing phosphanes PR3 or N-heterocyclic carbenes NHC 
and a second metallic fragment (based on titanocene [TiCp2][11-
16] or arene ruthenium(II) [Ru(p-cymene)Cl2(dppm)][17-19] 
derivatives). We unveiled the potential of these compounds as 
chemotherapeutics against renal, colorectal and prostate 
cancers (including mechanistic and in vivo studies). Second 
generation titanocene-based compounds (SG1 and SG2 in figure 
1) based on the bifunctional ligand mba = -OC(O)-p-C6H4-S- 
(derived from 4-mercaptobenzoic acid H2mba) resulted 
extremely efficacious in human clear cell renal carcinoma Caki-1 
cells[14,15] and xenograft mice[14] models. We demonstrated that 
these bimetallic compounds were more potent and affected a 
broader spectrum of molecular targets and cellular behaviors 
than any single isolate monometallic derivative.[15]  
Third generation titanocene-based compounds (TG1-4)[16] 
containing [Au(NHC)] fragments  (instead of [Au(PR3)]) resulted 
much less cytotoxic (500-100 times less efficient) on the renal 
cancer cells than the second generation compounds SG1-2. They 
however displayed relevant in vitro cytotoxic and apoptotic 
behavior and antimigratory properties in human prostate cancer 
(PC3) cell lines.[16] 
We report here on the preparation of modified third generation 
titanocene-gold bimetallic compounds of the type [(η5-
C5H5)2TiMe(μ-mba)Au(NHC)] (2a and 2b in Scheme 1) based on 
two highly active gold(I) compounds containing N-heterocyclic 
carbenes ([AuX(NHC)]; NHC = 1,3-Dibenzyl-4,5-
diphenylimidazol-2-ylidene NHC-Bn; X = Cl a; 1,3-Diethyl-4,5-
diphenylimidazol-2-ylidene NHC-Et; X = Br b) already 
described.[20,21] Both gold(I)-NHC compounds had been 
synthesized on the basis of relevant pharmacological properties 
of 4,5-diarylimidazoles[22] and the well-known antitumor 
properties displayed by gold(I) compounds containing either 
phosphanes [23,24] or N-heterocyclic carbenes.[25,26] Compound a 
(described by Tacke and co-workers[20,26,27]) and a variation with 
the 2’,3’,4’,6’-tetra-O-acetyl-β-D-glucopyranosyl-1’-thiolate 
showed very good activity against a wide range of human 
cancer cell lines from the NCI 60 cell line panel, and relevant 
tumor growth inhibition in vivo for a human clear cell renal 
carcinoma Caki-1 xenograft mice model.[27] More recently 
compound a has been bioconjugated to an engineered antibody 
(Thiomab LC-V2050) via cysteine conjugation. The anti-
proliferative activity of this ADC in HER2 positive breast cancer 
cell line showed a promising moderate improvement as 
compared to the gold-complex drug.[28] Compound b, described 
by Gust and co-workers in 2011, was found to be cytotoxic (low 
or sub-micromolar range) in breast and colon cancer cell 
lines.[21] 
We hypothesized that the incorporation of these highly cytotoxic 
gold(I) compounds and titanocene in the same molecule would 
improve their pharmacological profile. In addition to the 
synthesis, characterization and study of the stability of the new 
titanocene-gold compounds (and their monometallic precursors 
containing the mba linker, 1a and 1b in Scheme 1), we report on 
their cytotoxicity in human renal (Caki-1) and prostate (PC3) 
cancer cell lines, and their selectivity. We also report on the type 
of cell death induction, anti-migratory properties and inhibitory 
properties of TrRx and VEGF in prostate PC3 cancer cell lines 
for bimetallic compound 2a and precursor 1a. We include 
comparisons with the previously described[19] [AuX(NHC)] 
compound a. 
Results and Discussion 
Synthesis, characterization and stability studies 
 
The new compounds [(η5-C5H5)2TiMe(µ-mba)Au(NHC)] (NHC-
Bn 2a;  NHC-Et 2b in Scheme 1) are synthesized by reaction of 
precursors [Au(Hmba)(NHC)] (NHC-Bn 1a;  NHC-Et 1b) and [(η-
C5H5)2TiMe2] (Equation 1) via a procedure already reported.[14-16] 
All new compounds were obtained as white (1a-b) or yellow (2a-
2b) solids. The synthesis and characterization details are 
provided in the experimental section and NMR, IR and ESI-MS-
HR spectra are provided in the SI. The structures for the 
bimetallic compounds in Scheme 1 are proposed on the basis of 
analytical and spectroscopic data and by comparison with 
structurally-related compounds.[14-15] Compounds 2a and 2b are 
stable in solid state in air and at 5oC for months. ESI+-MS-HR 
spectra shows the parent peak for compound 2b as well as a 
peak (S17 and S18) for trimetallic species containing the Ti(η5-
C5H5)2Me(μ-mba) scaffold and two [Au(NHC-Et)] fragments 
(Figure S17). The identification of mutimetallic species by MS 
spectrometry (due to coordination of more than one [AuL]+ 
fragments to sulfur atoms under these conditions) is well 
known.[29] The ESI+-MS-HR spectra for 2a only shows the 
trimetallic species (S15 and S16). 
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Scheme 1. Preparation of [(η-C5H5)2TiMe(µ-mba)Au(NCH)] (NHC-Bn 2a; 
NHC-Et 2b). 
The diagnostic technique to assess the type of coordination of 
the carboxylate group from the mba ligand is IR spectroscopy. 
On the basis of the difference between symmetric and 
antisymmetric stretching bands in the solid state IR spectra of 
compounds 2a and 2b it is safe to propose a monodentate 
bonding for the carboxylate[30,31] as previously described by our 
group for both phosphine and NHC ligands, which was 
corroborated by DFT calculations.[14-16] In addition, we have 
performed more detailed DFT calculations in order to identify the 
coordination mode of the carboxylic group in bimetallic 
complexes 2a and 2b (see Figure 2 and in the SI, Table S1 and 
Figures S29 and S30). The relative position of symmetric and 
asymmetric stretching bands of the carboxylate groups can 
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distinctly characterize monodentate versus bidentate complexes. 
Both bands are observed in the experimental IR spectra; the 
symmetric strong band at 1284 cm-1 and the asymmetric 
moderate band at 1635 cm-1 for both 2a and 2b complexes. The 
observed difference of about 350 cm-1 indicates the 
monodentate coordination for these complexes. Moreover, the 
monodentate coordination mode was confirmed by DFT 
calculations where both coordination modes were modeled and 
compared to experimental spectra (Figures S29 and S30). For 
monodentate complexes the intense symmetric stretching band 
was computed around 1288 cm-1, and the asymmetric bands at 
1690 cm-1 that agrees with experimental bands and confirms the 
coordination mode. In contrast, for bidentate complexes the 
intense symmetric stretching band computed at 1456 cm-1 and 
the asymmetric band around 1523 cm-1 it is not in accordance 
with experimental spectra and excludes the bidentate 
coordination mode for these complexes. The most relevant 
distances calculated are collected in table S1 (SI).  
Unfortunately, we could not obtain crystals of enough quality for 
bimetallic compounds 2a and 2b for X-ray diffraction studies. 
 
 
Figure 2. Structure and atom labeling of compounds 2a (A) and 2b (B), shown 
at the energy-minimized geometry. For distances and angles see Table S1 in 
SI. 
 
The crystal structures of the monometallic precursors 1a and 1b 
were determined by X-ray (Figure 3 and in SI, Figures S31-S33 
and Tables S2 and S3). These structures are relevant due to the 
biological activity found for these precursors (see biological 
activity section). We have previously reported on the 
crystallography of compounds containing the mba linker and 
phosphane or N-heterocyclic carbene ligands.[14-16] The structure 
of 1a is depicted in Figure 3A. Its monomeric structure is almost 
identical to that obtained with a different NHC (ligand 3 in Figure 
1) and reported by us recently.[16] The structure of 1b is included 
in the SI information (S32) as it is extremely similar as well. For 
1a the environment of the gold atoms is close to linear [C-Au-S 
177.93(5)o] (Figure 3). A crystal structure of an analogue of 
compound a ((1,3-Di(p-methoxybenzyl)4,5-di(p-isopropyl 
phenyl)imidazol-2-ylidene)gold(I) chloride) had been already 
reported by Tacke et al.[20] The distance Au-C(1) of 2.0129(19) Å 
for 1a is close to that of compound a analogue of 1.988(3) Å. 
The angle of C(1)-Au-Cl(1) for the Tacke analogue is 180o 
(linear as in the case of 1a). For 1b (Figure S32 in SI) the angle 
is 174.33(8)o (still close to linearity) and the distortion most 
plausibly due to the supramolecular arrangement (Figure S33).  
A crystal structure of an analogue of b ([1,3-Diethyl-4,5-bis(4-
fluorophenyl)imidazol-2ylidene]gold(I) bromide) was also 
reported by Gust et al.[21] In this case the distance Au(1)−C(1) 
was 1.988(9)Å and the angle C(1)−Au(1)−Br(1) 178.3(2)o, again 
within the same range as for 1b where the C(1)-Au(1) distance 
is 2.010(3) Å and the angle a little shorter (174.33(8)o). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. A. ORTEP view of the molecular structure of 1a showing the 
labelling scheme. The labels for hydrogen and some carbon atoms are omitted 
for clarity. B. Crystal packing of 1a*CHCl3 showing the intermolecular contacts. 
The supramolecular packing is formed by hydrogen bonds (light blue lines) 
(1.782 Å), S···HCHCl3 (2.534 Å) and S···HPh (2.874 Å) (green lines) interactions.  
 
The most relevant characteristic of these compounds in solid 
state, is their ability to form supramolecular species via 
hydrogen bonding and in some specific cases via gold-gold 
interactions. In the case of compound 1a (Figures 3 and S31) 
the monomers organize into chains that are linked by short O-H 
bonds (1.782 Å). There are additional interactions between 
monomers and CHCl3 solvent molecules (interactions between 
the sulfur atom and one H from the CHCl3 molecule of 2.534 Å) 
as well as weaker interactions between the sulfur atom in one 
monomer and one hydrogen from a phenyl group in another 
monomer (2.874 Å). In the case of compound 1b (Figure S33) 
there are also short O-H bonds (1.871 Å) linking two different 
monomeric units and longer interactions between an oxygen 
from a monomer and one hydrogen from a phenyl group from a 
different monomer (2.589 Å).In these structures there are no 
appreciable gold-gold interactions. The shorter Au-Au distance 
observed for Au···Au 3.659 Å (1a) is a little above the sum of the 
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van der Waals radii of ca. 3.6 Å. The only compound that 
displayed monomers linked by gold-gold bonds, [(η5-
C5H5)2TiMe(μ-mba)Au(PEt3)] (SG2 in figure 1) has been 
reported recently.[16]  
 
The stability of compounds 2a and 2b was evaluated by 1H NMR 
spectroscopy in DMSO and DMSO/PBS (5:1) and by mass 
spectrometry over time (see SI). NMR experiments were 
performed in DMSO-d6 and in mixtures of DMSO-d6/PBS-D2O. 
The stability study of compounds 2a and 2b by 1H NMR in 
DMSO-d6 showed half-life values of 18 and 6 hours, respectively, 
considerably longer than former derivatives containing other 
NHC (third generation TG1-4 derivatives in Figure 1) with half-
lives ranging from 1 to 3 hours. The half-lives of 2a and 2b are 
also longer or in the same range as second generation 
compounds SG1-2 (Figure 1). Mass spectrometry further supports 
the presence of species containing both titanium and gold in 1% 
DMSO/PBS solution after 24 hours (see SI). We have shown in 
the past that the cyclopentadienyl ligands are dissociated over 
time, something we also observe for 2a and 2b.[14-16] In general, 
for titanocene-gold compounds we have been able to prove the 
co-localization of both metals (titanium and gold) both in cancer 
cells[14-16] and in tumors.[32] This fact indicates that the bimetallic 
compounds are pro-drugs that decompose into biological active 
species still containing a Ti-Au core.[32]  
 
Biological activity 
 
Cytotoxicity, selectivity and cell death  
 
The cytotoxicity of the bimetallic compounds [(η5-C5H5)2TiMe(µ-
mba)Au(NHC)] (NHC = NHC-Bn 2a, NHC-Et 2b), monometallic 
gold precursors [Au(Hmba)(NCH)] (NHC = NHC-Bn 1a, NHC-Et 
1b), the gold cytotoxic compounds ([AuX(NHC)]; NHC = NHC-
Bn; X = Cl a “Tacke”; NHC-Et; X = Br b “Gust”) already 
described,[11,12] and monometallic titanocene Y was evaluated. 
Titanocene Y (a compound described by the group of Tacke[33]) 
is considered a good benchmark for titanocenes due to its high 
activity in breast,[34,35] and renal[36] cancer in vitro and in vivo. For 
comparative purposes, the cytotoxic profile of cisplatin and 
Auranofin was also determined. In this assay, human clear-cell 
renal carcinoma Caki-1, human prostate PC3 cells and non-
tumorigenic human fetal lung fibroblasts (IRM-90) were 
incubated with the above described compounds for 72 hours. 
The compounds were assayed by monitoring their ability to 
inhibit cell growth using the PrestoBlue™ Cell Viability assay 
(see Experimental Section). The results are summarized in 
Table 1. 
 
The heterometallic compounds 2a and 2b are considerably more 
toxic to the renal (Caki-1) and prostate cancer cell lines (PC3) 
than cisplatin and Titanocene Y. They have a cytotoxicity similar 
to that of Auranofin but their selectivity is better. In this case and 
while gold compound [AuCl(NHC-Bn)] a had shown a 
cytotoxicity in the low micromolar range for these cell lines,[21] we 
found that the IC50 value with our method (PrestoBlue™ Cell 
Viability assay, 72 hours) was 27.7 ± 0.5 µM (similar to that of 
cisplatin and Titanocene Y). For gold compound b the 
cytotoxicity in these renal and prostate cancer cell lines had not 
been reported. The cytotoxicity of the compound with the mba 
linker 1a improves considerably with respect to compound a and 
the cytotoxicity of the bimetallic 2a is similar of that of 1a but its 
selectivity improves. For b the results are different since this 
compound resulted highly cytotoxic for both the renal and 
prostate cell lines while having a very good selectivity (see Table 
2). The modification of incorporating the mba linker (compound 
1b) decreases the cytotoxicity and selectivity which then 
improves by incorporation of the titanocene fragment (compound 
2b) but still this compound does not result as good as b in terms 
of cytotoxicity and selectivity combined. It is important to note 
that the cytotoxicity of the bimetallic compounds 2a and 2b in 
the renal cancer cell line Caki-1 improves considerably (5-13-
fold) when compared to previously described third generation 
compounds [(η5-C5H5)2TiMe(μ-mba)Au(NHC)] (TG1-4 in Figure 1) 
which displayed IC50 values in the range of 21-51 µM for this cell 
lines. For the prostate cancer cell lines the IC50 value of 2b (9.5 
µM) is in the range for those described for TG1-4 (9.8-17 µM) and 
compound 2a has a lower value at 3.9 µM. We choose 
compounds a, 1a and 2a and the cell line PC3 for further studies 
for better comparison with third generation compounds TG1-4 (in 
Figure 1). We also chose Auranofin as a control for our 
experiments (as we have done previously with other titanocene-
gold compounds[14-16]). 
 
 
Table 1. IC50 values (µM) for Caki-1, PC3 and IMR-90 treated with 
bimetallic 2a, 2b and monometallic a, 1a, b, 1b. Monometallic 
compounds Auranofin (AF), titanocene-Y (Ti-Y) and cisplatin (Structures 
in Chart 1) were used as controls.[a]  
Compound Caki-1 PC3 IMR-90 
a 27.7 ± 0.5 24.8 ± 0.5 84.4 ± 6.2 
1a 3.8 ± 0.1 3.7 ± 0.1 7.8 ± 0.5 
Ti-Au 2a 4.3 ± 0.1 3.9 ± 0.1 15.1 ± 3.3 
b 2.01 ± 0.3 11.8 ± 1.4 89.0 ± 7.7 
1b 9.2 ± 0.4 22.2 ± 0.4 38.1 ± 2.6 
Ti-Au 2b 5.0 ± 0.01 9.5 ± 0.3 12.6 ± 0.1 
Auranofin 2.8 ± 0.6b 3.6 ± 0.005 3.7 ± 0.4b 
Titanocene-Y 29.4 ± 4.2 58.1 ± 11.2 >100 
Cisplatin 23.9 ± 2.4b 6.7 ± 2.8 3.9 ± 0.5b 
a Compounds a, 1a, 1b and 2a were dissolved in a 1:1 solution of 
Triethylglycol and DMSO (1%), while compounds b, 2b, AF and Ti-Y were 
dissolved in 1% DMSO. Cisplatin was dissolved in H2O. All compounds were 
further diluted in cell culture media before addition to cells for a 72 h 
incubation period. The IC50 values are reported with the standard deviation of 
the sample mean (triplicates). b Values previously reported in reference [10]. 
 
 
Following the evaluation of the cytotoxicity of the compounds we 
proceeded to evaluate how the cells died. For this assay PC-3 
cells were incubated with monometallic gold compounds a, 1a 
Auranofin and bimetallic 2a at the IC50 concentration for 72 
hours. We observed that all the compounds induce apoptosis at 
their IC50 concentration (Figure 4). From these data, it can be 
deduced that compounds a, 1a and 2a induce similar apoptosis 
in prostate PC3 cancer cell lines after 72 hours (45-50%) while 
AF is more apoptotic (73%) in the same cell population. It should 
be highlighted however, that monometallic compound a has a 
considerably higher IC50 value than bimetallic 2a and thus, the 
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incorporation of the titanoce metallic fragment improves the 
apoptotic properties. 
Second generation compounds (SG1-2) had also diplayed 
relevant apoptotic behavior in renal cancer cells.[5-6] Third 
generation compounds [(η5-C5H5)2TiMe(μ-mba)Au(NHC)] (TG1[4 
in Figure 1) displayed apoptosis in PC3 cell lines as the major 
mode of cell death. However a quantification of apoptotic cells 
versus viable cells was not performed.[16] We have hypothesized 
that the apoptotic behavior of bimetallic titanocene-gold species 
comes from the two different metallic fragments[9,32] since both 
gold[38,39] and titanocene dichloride[40] are known to induce 
apoptosis in several cancer cell lines. 
 
 
Figure 4. Cell death induced in PC3 cells by the IC50 of a, 1a, 2a and 
Auranofin measured by flow cytometry after 72 h of incubation. The bar graph 
represents the quantification of cell death. Compound a, 1a and 2a induced 
apoptosis in 47%, 45 and 50% of the cell population while AF induced 
apoptosis in 73% of the cell population. 
 
 
Inhibition of migration by selected compounds 
 
Relevant anti-migration[14-16] and anti-invasion[15] properties have 
been found for titanocene-gold compounds in renal cancer cell 
lines, especially for the second generation compounds SG1-2. 
This is very important for the development of new anticancer 
chemotherapeutics as increased local cell migration and distal 
invasion are hallmarks of metastasis.[41] Two third-generation 
bimetallic titanocene-gold compounds TG1 and TG2 (in Figure 1) 
provided a reduction of migration of 46% and 55% in prostate 
cancer PC3 cells. The effect of compounds a, 1a, AF and 
bimetallic 2a on migration (at IC20 concentration) was 
determined using a wound-healing 2D scratch assay on a 
collagen-coated plate (Figure 5A). IC20 amounts are chosen 
because for these type of compounds at those concentrations 
around 80% of cells are alive and the effect measured is not due 
to cell death.[15] 
 
Figure 5B shows that bimetallic compound 2a reduces migration 
in ca. 92%. This reduction is significantly higher than that of 
Titanocene-Y (19%)[16] and that of the third generation bimetallic 
compounds already described TG1 and TG2 (Figure 1).[7] It is 
also slightly higher that that of AF (85%) in this cell line. For the 
renal cancer cell line Caki-1 we found that AF had a sightly or 
moderately higher migration inhibition than bimetallic 
compounds SG1-2.[15] We also found that the migration 
produced by bimetallic 2a is higher than that of monometallic 
precursor 1a or previusly described compound [AuCl(NHC)] a 
(92% 2a versus  66% 1a and 71% a at their corresponding IC20 
values) indicating again that there is an advantage in linking the 
titanocene fragment to the monometallic gold compound a. 
 
These results are quite significant since we have been able to 
correlate anti-migration with anti-invasion properties for 
titanocene-gold derivatives.[15] This means that these 
compounds may indeed have the potential to act as promising 
antimetastatic agents. Singaling molecules linked to migration 
and metastasis have also been inhibited significantly by second 
generation Ti-Au in renal cancer Caki-1 cell lines.[15] The 
potential for chemotherapeutics displaying both cytotoxicity and 
antimetastatic properties should be underscored. 
 
 
 
 
Figure 5. Cell migration assay for bimetallic compound 2a, and monometallic 
compound a, 1a and AF. Inhibition of migration (2D wound-healing scratch 
assay) by the IC20 of each compound. The assay indicates that 2a, 1a, and AF 
interfere with PC3 migration. A. The panels show the width of the scratch at 0, 
6, and 24 after it was inflicted. B. The bar graph represents the quantification 
of the cell migration at 48h relative to the 0h time-point.  
 
 
Inhibition of Thioredoxin Reductase (TrxR) and Vascular 
Endothelial Growth Factor (VEGF) by selected compounds 
 
Modification in the anti-oxidant profile of cancerous cells is 
characteristic of chemoresistance and is often accompanied by 
the overexpression of thioredoxin reductase (TrxR).[42,43] 
Increases in TrxR levels are critical to the mechanism of 
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cisplatin-resistant cells which renders it an attractive drug 
target.[44-46] Additionally, preventing the supply of nutrients and 
oxygen to the tumor site will hinder the tumor progession. 
Vascular endothelial growth factor (VEGF) is a key growth factor 
in angiogenesis, which potently stimulates the formation of blood 
vessels which allows tumor growth and progression.[47,48,49]  Gold 
compounds, including, Auranofin have been reported to 
significantly inhibit TrxR levels[14-16] and VEGF levels[15] in clear 
cell renal carcinoma Caki-1 and prostate cancer PC3 cell lines. 
 
 
 
Figure 6. A. Immunofluorescent analysis of TrRx level upon treatment with 
control (0.1 % DMSO), a, 1a, 2a or Auranofin (AF) in 0.1% DMSO for 24 h. 
Thioredoxin reductase (green) in the PC3 cells and its levels are changed in 
response to treatment with compounds of interest. B. Quantitative analysis of 
TrRx levels using ImageJ showing significant decreasing the enzyme level 
following exposure to 2a and AF compared to control. All data in bar graphs 
represent mean ± SD of two independent experiments ( p < 0.05).  
  
Immunocytochemistry is a technique that allows direct 
visualization of the presence, intensity or absence of a cellular 
protein of interest through the use of fluorescently labeled 
antibodies. The fluorescent signal emitted results from the highly 
specific binding of antibodies to their unique antigens.[50,51] In 
order to detect all cells, the DNA-labeling dye DAPI is used as it 
labels in blue each nuclei corresponding each to one cell. DAPI 
positive spots are used to obtain the total cell count in a given 
sample. Phalloidin is used to label the actin protein, which 
makes up most of mammalian cell’s cytoskeleton and here emits 
a red signal. Through phalloidin positive staining cytoskeletal 
integrity can be assessed. In the experiment described here, we 
have also used a fluorescent-labeled antibody for TrxR, colored 
green, and for VEGF, colored yellow. Through this experiment 
we aim to determine to which extent the treatment with the 
metallo-complexes being studied inhibit or lead to the 
overexpression of TrRx and VEGF. 
 
 
 
Figure 7. A. Immunofluorescent analysis of VEGF level upon treatment with 
control (0.1 % DMSO), a, 1a, 2a or Auranofin (AF) in 0.1% DMSO for 24 h. 
VEGF (yellow) in the PC3 cells and its levels are changed in response to 
treatment with compounds of interest. B. Quantitative analysis of VEGF levels 
using ImageJ showing significant decreasing the protein levels following 
exposure to 2a and AF compared to control. All data in bar graphs represent 
mean ± SD of two independent experiments ( p < 0.05).  
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The results obtained for the inhibition of TrRx experiment (Figure 
6) indicate that a ([AuCl(NHC-Bn)]  or “Tacke”  compound) 
inhibits only 3% of TrxR in the assay conditions (IC20 
concentrations and 24 h incubation time). Compound 1a inhibits 
12% of TrxR activity while 2a inhibits TrxR activity by 38% a 
reflected by the decrease of TrxR positive cells. The inhibition of 
TrxR by the bimetallic compound 2a is within the same range 
than that of AF that with this assay affords an ihibition of 46%. 
The results obtained for the inhibition of VEGF experiment 
(Figure 7) indicate that a ([AuCl(NHC-Bn)]  or “Tacke”  
compound) reduces 25% of VEGF expression in assay 
conditions (IC20 concentrations and 24 h incubation time). 
Compound 1a reduces 13% of VEGF activity while 2a reduces 
44% of VEGF activity. Their reduction is reflected by the 
decrease of VEGF in positive cells (control). The reduction of 
VEGF by the bimetallic compound 2a is also within the same 
range that of AF (50% of VEGF reduction).  
 
It is clear that the incorporation of the titanocene fragments to 
compound a improves significantly its TrxR and VEGF inhibitory 
properties as we have already reported for second[14,15] and third 
generation[16] titanocene-gold compounds containing phosphane 
and N-heterocyclic carbene ligands. The improvement 
presented here is however quite remarkable. 
Conclusions 
In conclusion, we have synthesized bimetallic compounds 
containing titanocenes and gold(I)-N-heterocyclic carbene 
fragments which were already known to display relevant 
anticancer properties in vitro and in vivo. We have demonstrated 
that the incorporation of the titanocene fragment improves or 
does not decrease the cytotoxicity in the human cancer cell lines 
Caki-1 and PC3. We have demonstrated that a selected 
bimetallic compound derived from monometallic “Tacke” 
[AuCl(NHC-Bn)] has an improved pharmacological profile in 
terms of apoptosis, inhibition of migration, and inhibition of 
thioredoxin reductase and VEGF in prostate cancer cell lines 
with respect to the monometallic bioactive gold compound. The 
work presented here supports the idea that bimetallic 
compounds can indeed be designed to contain two different 
active metal-based fragments (and allow for synergistic and/or 
cooperative effects) by judicious choice of the linker. 
Experimental Section 
General information and instrumentation for synthesis, 
characterization and stability studies of the new compounds 
NMR spectra were recorded in a Bruker AV400 (1H-NMR at 400 MHz 
and 13C{1H} NMR at 100.6 MHz). Chemical shifts (δ) are given in ppm 
and coupling constants (J) in Hertz (Hz), using CDCl3, d6-DMSO or PBS-
D2O as solvent, unless otherwise stated. 1H and 13C NMR resonances 
were measured relative to solvent peaks considering tetramethylsilane = 
0 ppm. IR spectra (4000-500 cm-1) were recorded on a Nicolet 6700 
Fourier transform infrared spectrophotometer on solid state (ATR 
accessory). Elemental analyses were performed on a Perkin-Elmer 2400 
CHNS/O series II analyzer by Atlantic Microlab Inc. (US). Mass spectra 
electrospray ionization high resolution (MS-ESI-HR) were performed on a 
Waters Q-Tof Ultima. The theoretical isotopic distributions have been 
calculated using enviPat Web 2.0.  
 
Synthesis and characterization 
[AuCl(tht)],[52] [AuX(NHC)] (X = Cl, Br),[20,21] and Cp2TiMe2[53] were 
prepared as previously reported. Chemicals were purchased as 
indicated: Cp2TiCl2, H[AuCl4] (STREM Chemicals), 4-mercaptobenzoic 
acid (H2mba) and Methyl Lithium solution (1.6M) (Sigma Aldrich). 
Reaction solvents were purchased anhydrous from Fisher Scientific 
(BDH, ACS Grade) and Sigma-Aldrich, used without further purification, 
and dried in a SPS machine and kept over molecular sieves (3 Å, beads, 
4-8 mesh), otherwise over sodium if necessary. Deuterated solvents 
were purchased from Cambridge Isotope Laboratories, Inc. and were 
kept over molecular sieves (3 Å, beads, 4-8 mesh). Celite (Celite 545, 
Diatomaceous Earth) was purchased from VWR International and used 
as received.  
 
General Procedure for [Au(Hmba)(NHC)] (1a, 1b). H2mba (0.061 g, 0.395 
mmol) was added to a solution of KOH (0.022 g, 0.395 mmol) in 20 mL of 
ethanol (16 mL) and water (4 mL) and stirred for 20 minutes at room 
temperature. [AuX(NHC)] (X = Cl, Br) (0.250g, 0.395 mmol) was added to 
the previous solution and stirred for 5 hours. Solvents were removed 
under reduced pressure, and the residue was washed with water (3 × 5 
mL) and 10 ml of mixture of diethyl ether /hexane (3:2) to afford 1a, 1b as 
white solids. 1a (NHC-Bn): 81% yield (0.241 g). Anal. Calcd. for 
C34H43AuN2O2S: C, 57.60; H, 3.86; N, 3.73; S, 4.27. Found: C, 57.40; H, 
3.77; N, 3.66; S, 4.15. 1H NMR (CDCl3): δ 5.49 (s, 4H, CH2), 7.04 (d, 3JHH 
= 7.2 Hz, 4H, ArH), 7.10 (dd, 3JHH = 6.7 Hz, 2JHH = 2.5 Hz, 4H, ArH), 
7.24-7.29 (m, 10H, ArH), 7.34 (t, 3JHH = 7.3 Hz, 2H, ArH), 7.52 (d, 3JHH = 
8.4 Hz, 2H, ArH), 7.68 (d, 3JHH = 8.5 Hz, 2H, ArH). 13C{1H} NMR (CDCl3): 
δ 52.64 (s, CH2), 123.12 (s, 4-C6H4), 127.24 (s, 2-C6H5), 127.33 (s, 1-
C6H5), 128.12 (s, 3-C6H5), 128.63 (s, 3-C6H5), 128.71 (s, 4-C6H5), 129.37 
(s, 4-C6H5), 129.44 (s, 3-C6H4), 130.68 (s, 2-C6H5), 131.87 (s, 2-C6H4), 
132.10 (s, C-imidazole), 135.91 (s, 1-C6H5), 153.81 (s, 1-C6H4) 172.07 (s, 
C=O), 182.40 (s, C-carbene). IR (cm-1): 2947 m,br (OH), 2322 m, 1667 s, 
1580 s (νasym CO2), 1417 m, 1281 s (νsym CO2), 1168 s, 1084 s, 766 s. 
MS (ESI): m/z Calcd 750.67. Found: 997.35 [NHC-Au-NHC]+. 1b (NHC-
Et): 77% (0.174 g). Anal. Calcd. for C26H25AuN2O2S: C 49.84; H 4.02; N 
4.47; S 5.12. Found: C, 49.56; H, 4.02; N, 4.66; S, 4.89.  1H NMR 
(CD3Cl3): δ 1.35 (t, 3JHH = 7.21 Hz, 6H, CH3), 4.24 (q, 3JHH = 7.27 Hz, 4H, 
CH2), 7.20-7.22 (m, , 2JHH = 1.85Hz, 10H, ArH), 7.36-7.37 (m, , 2JHH = 
1.85 Hz, 3JHH = 5.17 Hz, 2H, ArH), 7.73 (d, 3JHH = 8.54 Hz, 6H, ArH), 7.79 
(d, 3JHH = 8.54 Hz, 4H, ArH). 13C{1H} NMR (CD3Cl3): δ 17.23 (s, CH3), 
44.33 (s, CH2), 127.93 (s, 4-C6H4), 129.01 (s, 2,4-C6H5), 129.47 (s, 1-
C6H4), 129.67 (s, 2-C6H4), 130.63 (s, 2-C6H5 ), 131.29 (s, C imidazole), 
132.10 (s, 3-C6H4), 170.88 (s, C = O), 179.76 (s, C-carbene).  IR (cm-1): 
2953 m,br (OH), 2364 m, 1678 s, 1577 s (νasym CO2), 1399 s (νsym CO2), 
1259 m, 1116 m, 1080 m, 764 m. MS (ESI): m/z Calcd 626.52. Found: 
749.28 [NHC-Au-NHC]+. 
 
General Procedure for [(η5-C5H5)2TiMe(μ-mba)Au(NHC)] (2a,2b). The 
corresponding monometallic gold precursor (1a, 1b) (0.220 mmol) was 
dissolved in tetrahydrofuran (15 mL) and added via addition funnel over a 
solution of Cp2TiMe2 (0.046 g, 0.220 mmol) in toluene (5 mL) under 
nitrogen. The resulting bright orange solution was stirred for 45 minutes 
at room temperature. The solution was filtered off and the solvents were 
then removed under reduced pressure to afford an oily solid that was 
washed with diethyl ether (3 × 5 mL) and hexane (3 x 5 mL) to yield a 
yellow solid. 2a: (NHC-Bn): 46% yield (0.120 g). Anal. Calcd. for 
C47H41AuN2O2STi•1.5H2O: C, 58.21; H, 4.58; N, 2.98; S, 3.31. Found: C, 
58.05; H, 4.50; N, 2.76; S, 3.55. 1H NMR (CDCl3): δ 0.97 (s, 3H, Ti-CH3), 
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5.46 (s, 4H, CH2), 6.19 (s, 10H, Cp), 7.01 (d, 3JHH = 7.2 Hz, 6H, ArH), 
7.06 (d, 3JHH = 6.7 Hz, ArH, 5H), 7.22-7.23 (m, ArH, 5H), 7.27-7.33 (m, 
ArH, 6H), 7.42 (d, 3JHH = 8.4 Hz, ArH, 2H). 13C{1H} NMR (CDCl3): δ 43.98 
(s, Ti-CH3), 52.64 (s, CH2), 114.26 (s, Cp), 127.31 (s, 2-C6H5), 127.37 (s, 
1-C6H5), 128.04 (s, 4-C6H4), 128.58 (s, 3-C6H5), 128.64 (s, 4-C6H5), 
129.24 (s, 4-C6H5), 129.29, (s, 3-C6H4), 130.69 (s, 2-C6H5), 131.68 (s, 2-
C6H4), 132.02 (s, C-imidazole), 135.91 (s, 1-C6H5), 149.69 (s, 1-C6H4), 
171.77 (s, C=O), 182 (s, C-carbene). IR (cm-1): 2953 m (Cp), 1632, 1580 
m (νasym CO2), 1444 s, 1281 vs (νsym CO2), 1165 m (Cp), 1083 m (Cp). 
2b: (NHC-Et): 26% yield (0.046 g). Anal. Calcd. for 
C37H37AuN2O2STi•1/2C7H9: 54.29; H, 4.56; N, 3.42; S, 3.92. Found: C, 
55.64; H, 5.07; N, 3.21; S, 3.38. 1H NMR (CDCl3): δ 0.97 (s, 3H, Ti-CH3), 
1.35 (t, 3JHH = 7 Hz, 6H, CH3), 4.23 (q, 3JHH = 7.4 Hz, 4H, CH2), 6.20 (s, 
10H, Cp), 6.16-7.22 (m, 5H, ArH), 7.35-7.37 (m, 4H, ArH), 7.40 (d, 3JHH = 
8.6 Hz, ArH, 2H), 7.63 (d, 3JHH = 8.3 Hz, 2H, ArH). 13C{1H} NMR (CDCl3): 
δ 17.05 (s, CH3), 43.92 (s, Ti-CH3), 44.15 (s, CH2), 114.27 (s, Cp), 
127.81 (s, 4-C6H4), 128.19 (s, 1-C6H5), 128.81 (s, C6H5), 129.23 (s, C6H5), 
129.30 (s, 3-C6H4), 130.48 (s, C6H5), 131.06 (s, C-imidazole), 131.73 (s, 
2-C6H4), 150.05 (s, 1-C6H4), 171.91 (s, C=O), 182.26 (s, C-carbene). IR 
(cm-1): 2951 m (Cp), 2338 m, 1635 m, 1581 (νasym CO2), 1441 m, 1279 
m (νsym CO2), 1168 s (Cp), 1080 s (Cp). 
 
DFT calculations  
Calculations of compounds 2a and 2b have been carried out with the 
hybrid density functional method B3LYP as implemented in 
Gaussian09.[54] Structures were optimized as in a gas phase using 6-
311G(d) basis set for all atoms but Au for which the all-electrons DPZ 
plus polarization basis set was implemented and obtained from the 
EMSL Basis Set Library.[55,56] The stability of optimized structures has 
been verified by performing frequency calculations at the same level of 
theory. Both mono-dentate 2a and 2b complexes were computed to be 
stabilized over the corresponding bi-dentate complexes by about 3.9 
kcal/mol. All computed frequencies for optimized structures were positive 
and their computed normal mode displacements were employed to 
predict infra-red intensities. Computed spectra were simulated by a 
Lorentzian broadening with a band width of 30 cm-1 on half height of 
each band.    
Crystal structure determination 
Colorless single crystals were obtained by slow diffusion of n-
hexane into solutions of the complex in CHCl3 (1a -30ºC) or THF 
(1b 0 ºC). The diffraction data were collected using graphite 
monochromatic Mo-Kα radiation with a Bruker APEX-II 
diffractometer at a temperature of 120 K using the APEX-II 
software. Structures were solved by Intrinsic Phasing using 
SHELXT[57] and refined by full-matrix least squares on F2 with 
SHELXL.[58] The absorption correction was performed using 
MULTISCAN[59] with the WINGX program suite.[60] All non-hydrogen 
atoms were assigned anisotropic displacement parameters. The 
hydrogen atoms were positioned geometrically, with isotropic 
parameters 1.2 times the Uiso value of their attached carbon for the 
aromatic and methylene hydrogens and 1.5 times for the methyl 
groups. For 1a one molecule of CHCl3 was found in the asymmetric 
unit, giving rise the stoichiometry 1a•CHCl3. The structure of 1b 
shows some residual peaks greater than 1 e Å−3 in the vicinity of 
the gold atom, with no chemical meaning. These data can be 
obtained free of charge from The Cambridge Crystallographic Data 
Center via www.ccdc.cam.ac.uk/data_request/cif (CCDC 1882280 1a 
and CCDC 1882281  1b) or in the Supplementary Information.  
 
 
 
Cell lines 
Human renal clear cell carcinoma line Caki-1 and human prostate 
adenocarcinoma line PC3 were obtained from the American Type Culture 
Collection (ATCC) (Manassas, Virginia, USA) and cultured using Roswell 
Park Memorial Institute (RPMI-1640) (Fisher Scientific,  Hampton, NH) 
media containing 10% Fetal Bovine Serum, certified, heat inactivated, US 
origin (FBS) (Fisher Scientific,  Hampton, NH), 1% Minimum Essential 
Media (MEM) nonessential amino acids (NEAA) (Fisher Scientific,  
Hampton, NH), and 1% penicillin-streptomycin (PenStrep) (Fisher 
Scientific,  Hampton, NH). Human fetal lung fibroblast IMR90 cells were 
purchased from ATCC (Manassas, Virginia, USA) and cultured using 
Dulbecco’s modified Eagle’s medium (DMEM) (Fisher Scientific,  
Hampton, NH) supplemented with 10% FBS, 1% MEM-NEAA, and 1% 
PenStrep. All cells were cultured at 37 °C under 5% CO2 and 95% air in 
a humidified incubator.  
 
Cell viability analysis 
The cytotoxic profile (IC50) of the compounds were determined by 
assessing the viability of PC3, Caki-1 and IMR90 cells. Cells were 
seeded at a concentration of 5 x 103 cells/well in 90 µL of appropriate 
complete media without phenol red into tissue culture grade 96-well flat 
bottom microplates (BioLite Microwell Plate, Fisher Scientific, Waltham, 
MA) and grown for 24 h at 37 °C under 5% CO2 and 95% air in a 
humidified incubator. The compounds a, 1a, 1b and 2a were dissolved in 
a 1:1 solution of Triethylglycol and DMSO, while compounds b, 2b, AF 
and Ti-Y were dissolved in DMSO. Cisplatin was dissolved in H2O. The 
intermediate dilutions of the compounds were added to the wells (10 µL) 
to obtain concentration of 0.1 µM, 1 µM, 10 µM, 50 µM and 100 µM, 
0.1% DMSO was used as control, and the cells were incubated for 72 h. 
Presto Blue was used to quantitively measure variations in cell viability of 
treated cells. Following 72 h drug exposure, 11 µL per well of 10x 
PrestoBlue (Invitrogen, Carlsbad, CA) labeling mixture was added to the 
cells at a final concentration of 1x and incubated for 1 h at 37 °C under 
5% CO2 and 95% air in a humidified incubator. The optical fluorescence 
of each well in a 96-well plate was quantified using a BioTek Synergy 
Multi-mode microplate reader (BioTek Instruments, Inc., Winooski, VT) 
set at 530/25 excitation nm and 590/35 nm emission. The percentage of 
surviving cells was calculated from the ratio of absorbance of treated to 
untreated cells. The IC50 value was calculated as the concentration 
reducing the proliferation of the cells by 50% and is presented as a mean 
(±S.EM) of at least two independent experiments each with triplicate 
measurements. 
 
Cell death assay 
For the assessment of the cell death in PC3, cells were cultured in 100 
mm tissue culture dishes (Fisher Scientific,  Hampton, NH) using RPMI 
phenol red free medium and reach a growth ~75% confluency. The cells 
were dose using the IC50 of compounds a, 1a, 2a, AF and incubated for 
72 h at 37 °C under 5% CO2 and 95% air in a humidified incubator. Then, 
cells were collected using trypsin (Fisher Scientific,  Hampton, NH) to 
later count with a hemocytometer and prepare 25 x104 cells/sample. 
After the samples were prepared, the cells in the samples were 
centrifuged, supernatant was aspirated from the pallet, and washed 
gently one time with PBS. The cells were centrifuged again, PBS was 
aspirated and eBioscience Annexin V-FITC Apop Kit (Invitrogen, 
Carlsbad, CA) was used to labeled cells as follows, the cells were 
resuspended in 195 µL of 1x binding buffer and 5 µL of Annexin-V dye 
was added. The cells were incubated at room temperature for 10 min. 
After the incubation period finished, cells were washed one time with 1x 
binding buffer and resuspended in 190 µL of 1x binding buffer with 10 µL 
of propidium iodide. The dye’s fluorescence intensity was detected via 
10.1002/cmdc.201800796
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemMedChem
This article is protected by copyright. All rights reserved.
FULL PAPER    
9 
 
flow cytometry using a BD C6 Accuri flow cytometer. 10 x 105 events per 
sample were recorded. The flow cytometer was calibrated prior to each 
use.  
 
Cell migration analysis 
PC3 cells were allowed to seed in fibronectin-coated 6-well plate 
(Corning Incorporated, Durham, NC) and grown a monolayer of ~90% 
confluency. After which, the monolayer was scratched using a 200 µL tip. 
The complete medium and cells detached due to the scratch were 
aspirated and replaced with serum-free medium. The antimigratory 
profiles of bimetallic compound 2a, monometallic compounds a, 1a, and 
AF was assessed with the IC20 of each compound. The diluting agent 
(1:1, triethylglycol: DMSO) served as a negative control. Cells were 
incubated at 37 °C under 5% CO2 and 95% air in a humidified incubator. 
At 0, 6, 24 and 48 h after the scratch, cells were photographed using a 
Leica MC120 HD mounted on a Leica DMi1 microscope at 5x 
magnification. The area invaded was measured in five randomly selected 
segments from each photo then averaged. Data were collected from two 
independent experiments. 
 
Immunohistochemistry 
Cells were seeded in an 8-well millicell slide (Millipore, sigma) at a 
concentration of 25000 cells/well  in a humidified atmosphere of 95% 
air/5% CO2 at 37 °C. 24h post seeding, cells were treated with the IC20 of 
bimetallic compound 2a, monometallic compound a, 1a, and as control 
AF and incubated for 24 h. Cells were fixed using 4% PFA and incubate  
at room temperature for 15 min. The PFA was removed and the wells 
were washed three times with PBS. Cells were handled carefully as to 
maintain cellular integrity. The cells were then blocked with 5% BSA 
(Fisher Scientific,  Hampton, NH), 0.3% Triton-X100 (Acros Organics, 
Morris Plains, NJ, USA) in PBS for 1h at room temperature. The blocking 
solution was then removed and the wells were washed three times with 
PBS. After the washes with PBS, cells were incubated overnight at 4 °C 
with the respective antibodies. TrxR activity in cells was visualized using 
an rabbit anti-thioredoxin antibody (Novus biological, Littleton, CO). 
VEGF activity was obtained by using mouse anti-VEGF antibody (Novus 
biological, Littleton, CO) and goat anti-mouse secondary antiody (Fisher 
Scientific,  Hampton, NH). Then, the antibodies solution was removed 
from the slide and anti-phalloidin antibody (Cell Signaling Technology, 
Danvers, MA) to visualize the cytoskeleton of the cells. After 1 h of 
incubation at room temperature, cells were washed three times with PBS 
and one drop per well of DAPI containing ProLong Gold Antifade 
Mounting Medium (Invitrogen, Carlsbad, CA) was used to visualize the 
nuclei and mount the slide.  
 
Analysis of cell TrxR, VEGF, Phalloidin and DAPI. 
Following immunohistochemical processing all stained samples were 
imaged at 10x magnification using Fluoview FV10i (Olympus America 
Inc., Center Valley, PA). Cell were quantified one channel at a time using 
ImageJ, and the percentage of rabbit anti-thioredoxin antibody positive 
per DAPI positive cells were calculate per field of view over 5 fields of 
view. 
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